NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

26.76 +0.56 (+2.14%)
At close: August 7 at 4:04:04 PM EDT
26.67 -0.09 (-0.34%)
After hours: August 7 at 7:59:51 PM EDT
Trade Pfizer on Coinbase
Chart Range Bar
Loading chart for PFE

News headlines Pfizer has raised its 2026 revenue guidance to $61.5 billion, driven by strong non-COVID product performance, while navigating challenges from declining COVID product sales. The company's stock may be undervalued at $25.81, with analysts noting potential upside despite ongoing market pressures.

Pfizer has raised its 2026 revenue guidance to $61.5 billion, driven by strong non-COVID product performance, while navigating challenges from declining COVID product sales. The company's stock may be undervalued at $25.81, with analysts noting potential upside despite ongoing market pressures.

Updated 15m ago · Powered by Yahoo Scout
  • Previous Close 26.20
  • Open 26.22
  • Bid 26.69 x 2880000
  • Ask 26.68 x 1170000
  • Day's Range 26.05 - 26.76
  • 52 Week Range 23.58 - 28.75
  • Volume 36,137,077
  • Avg. Volume 41,893,461
  • Market Cap (intraday) 152.523B
  • Beta (5Y Monthly) 0.28
  • PE Ratio (TTM) 35.21
  • EPS (TTM) 0.76
  • Earnings Date (est.) Nov 3, 2026
  • Forward Dividend & Yield 1.72 (6.43%)
  • Ex-Dividend Date Jul 24, 2026
  • 1y Target Est 28.63

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

75,000

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 8/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PFE
13.02%
S&P 500 (^GSPC)
13.32%

1-Year Return

PFE
18.19%
S&P 500 (^GSPC)
22.36%

3-Year Return

PFE
9.04%
S&P 500 (^GSPC)
71.69%

5-Year Return

PFE
22.64%
S&P 500 (^GSPC)
74.86%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 15.03B
Earnings -248M

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
5B
10B
15B
 

Analyst Insights

View More

Top Analyst

RBC Capital
45/100
Latest Rating
Sector Perform
 

Analyst Price Targets

25.00 Low
28.63 Average
26.76 Current
35.46 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 8/7/2026
Analyst Guggenheim
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 35 -> 31
 

Statistics

View More

Valuation Measures

Annual
As of 8/7/2026
  • Market Cap

    152.52B

  • Enterprise Value

    204.02B

  • Trailing P/E

    35.21

  • Forward P/E

    9.07

  • PEG Ratio (5yr expected)

    2.59

  • Price/Sales (ttm)

    2.41

  • Price/Book (mrq)

    1.79

  • Enterprise Value/Revenue

    3.20

  • Enterprise Value/EBITDA

    15.12

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.80%

  • Return on Assets (ttm)

    5.78%

  • Return on Equity (ttm)

    5.01%

  • Revenue (ttm)

    63.7B

  • Net Income Avi to Common (ttm)

    4.34B

  • Diluted EPS (ttm)

    0.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.7B

  • Total Debt/Equity (mrq)

    74.25%

  • Levered Free Cash Flow (ttm)

    12.49B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

26.76 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

Research Reports

View More
  • The market took a much-needed rest on Wednesday, which

    The market took a much-needed rest on Wednesday, which is a technical a positive. The last thing we need is a parabolic, blow-off move. While the rally was only four days, investors may have been chasing returns. The best action that can endure for the longest time is a simple crawl higher (never too hot or too cold). Parabolic advances typically are ending moves (just look at what happened to metals, crypto currencies, and some semiconductor stocks this year).

     
  • Strong growth from non-COVID products

    Pfizer is a leading developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.

    Rating
    Price Target
     
  • Daily – Vickers Top Buyers & Sellers for 08/06/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Pfizer Earnings: Strong Growth for Newer Drugs Counters Covid Declines; Maintaining $32 FVE

    Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

    Rating
    Price Target
     

People Also Watch